TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

NCT02065362 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

EBV-positive Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL: DNR.NPC-specific T cells
BIOLOGICAL: DNR.NPC-specific T cells + cyclophosphamide + fludarabine

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]
[object Object]